Mitochondrial Proteostasis Compounds for Amyloid-Beta Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective in treating or delaying amyloid-β peptide diseases such as Alzheimer's and inclusion body myositis, as they primarily focus on counteracting amyloid-β aggregation without addressing mitochondrial dysfunction, which is a key pathological hallmark of these conditions.
Innovation Solution
Administering therapeutically effective amounts of compounds that enhance mitochondrial proteostasis, including inducing mitochondrial unfolded protein response, biogenesis, mitophagy, and modulating lipid metabolism, using specific compounds like tetracyclines, NAD+ boosters, PARP inhibitors, and statins to improve mitochondrial function and reduce amyloid-β aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If therapies focus on counteracting amyloid-β aggregation, then amyloid-β aggregation is reduced, but mitochondrial dysfunction is not addressed and disease progression continues
Solution Approach 1:
The therapy is segmented into two distinct components: (1) compounds that counteract amyloid-β aggregation, and (2) compounds that enhance mitochondrial proteostasis. This segmentation allows each component to address specific pathological aspects independently, with the mitochondrial proteostasis component specifically targeting the mitochondrial dysfunction that limits the effectiveness of amyloid-β aggregation therapies alone.
Solution Approach 2:
The patent merges two therapeutic approaches into a single treatment regimen: anti-amyloid-β aggregation therapy combined with mitochondrial proteostasis enhancement therapy. This combination addresses both the amyloid pathology and the mitochondrial dysfunction that occurs in diseases like Alzheimer's and inclusion body myositis, thereby improving overall therapeutic effectiveness.
2Reliability
If compounds that enhance mitochondrial proteostasis are administered, then mitochondrial function is improved and amyloid-β aggregation is reduced, but the treatment targets previously unaddressed pathological mechanisms
Solution Approach 1:
The patent identifies mitochondrial proteostasis enhancement as a universal therapeutic mechanism that benefits multiple amyloid-β related diseases, including Alzheimer's disease and inclusion body myositis. By targeting the common pathological feature of mitochondrial dysfunction across these different diseases, a single therapeutic approach can be applied universally to improve outcomes in various conditions.
3Duration of action of stationary object
If mitochondrial proteostasis is enhanced through multiple mechanisms, then mitochondrial function is stabilized and healthspan is improved, but the number of therapeutic targets increases
Solution Approach 1:
The patent promotes continuous mitochondrial proteostasis enhancement through multiple mechanisms including induction of mitochondrial unfolded protein response (UPRmt), stimulation of mitochondrial biogenesis, and activation of mitophagy. These continuous actions work together to maintain mitochondrial function over extended periods, thereby improving healthspan and delaying disease progression in a sustained manner.
Data Source
AI summary
The present invention is directed to a method of treating an amyloid-β peptide disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound that enhances mitochondrial proteostasis.